Biographies

E-mail this page

(All fields required)

Recipient's email address

Please enter a valid email.

Your name

Please enter your name.

Your email address

Please enter a valid email.

Find another Doctor or Researcher

High Res

J. Pablo Abonia, MD

Interim Director, Registry for Eosinophilic Disorders (REGID)

Associate Professor, UC Department of Pediatrics

Phone: 513-636-9463

Fax: 513-636-3310

Email: pablo.abonia@cchmc.org

Show All

Specialties

Eosinophilic and mast cell disorders; immunodeficiency

Biography

J. Pablo Abonia, MD, provides the bulk of the clinical allergy care for patients with eosinophilic disease. He is currently involved in a multicenter clinical research trial of anti-IL5 (reslizumab) for patients with eosinophilic esophagitis. His research focuses on mining the research databanks (patient characteristics, tissue samples, RNA and DNA) to elucidate the mechanisms, diagnosis and treatment of eosinophilic esophagitis, and he is the Interim Director of the Registry for Eosinophilic Disorders (REGID). He is particularly interested in the role of mast cells in eosinophilic esophagitis.

Education and Training

MD: University of Buffalo, Buffalo, NY, 1997.

Residency: Pediatrics, Children's Hospital of Buffalo, Buffalo, NY, 2000.

Certification: American Board of Pediatrics, 2001; American Board of Allergy and Immunology, 2003.

Publications

View PubMed Publications

Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med. 2012;63:421-34.

Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb;129(2):456-63.

Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol. 2012 Apr;129(4):1064-75.

Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, Rothenberg ME. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012 Jun;129(6):1570-8.

Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? Child Care Health Dev. 2012 Jul;38(4):477-83.

Franciosi JP, Hommel KA, Greenberg AB, Debrosse CW, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of the Pediatric Quality of Life Inventory Eosinophilic Esophagitis Module items: qualitative methods. BMC Gastroenterol. 2012 Sep 25;12(1):135.

Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011 Jul;7(4):411-7.

Debrosse CW, Franciosi JP, King EC, Buckmeier Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa'ad A, Putnam PE, Rothenberg ME. Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol. 2011 Jul;128(1):132-8.

Abonia JP, Castells M. Drug allergy in pediatric patients. Pediatr Ann. 2011 Apr;40(4):200-4.

Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011 Nov 18;11:126.